Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 16 | 2023 | 128 | 5.040 |
Why?
|
| HIV Infections | 11 | 2023 | 4946 | 1.430 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 137 | 1.330 |
Why?
|
| Hypertension | 2 | 2023 | 397 | 1.110 |
Why?
|
| Obesity | 2 | 2023 | 356 | 0.690 |
Why?
|
| Female | 19 | 2023 | 8751 | 0.690 |
Why?
|
| South Africa | 20 | 2023 | 7312 | 0.690 |
Why?
|
| Neoplasms | 4 | 2023 | 141 | 0.670 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 251 | 0.620 |
Why?
|
| Humans | 23 | 2023 | 14077 | 0.610 |
Why?
|
| Middle Aged | 9 | 2022 | 3425 | 0.470 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 41 | 0.380 |
Why?
|
| Survival Analysis | 2 | 2021 | 149 | 0.360 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 19 | 0.320 |
Why?
|
| Prevalence | 3 | 2022 | 1149 | 0.310 |
Why?
|
| Cohort Studies | 4 | 2022 | 939 | 0.270 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2023 | 7 | 0.270 |
Why?
|
| Tamoxifen | 2 | 2023 | 9 | 0.270 |
Why?
|
| Prospective Studies | 4 | 2022 | 1131 | 0.270 |
Why?
|
| Multimorbidity | 2 | 2023 | 42 | 0.260 |
Why?
|
| Chronic Disease | 2 | 2023 | 100 | 0.250 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 163 | 0.240 |
Why?
|
| Hospital Mortality | 2 | 2021 | 94 | 0.230 |
Why?
|
| Age Factors | 3 | 2019 | 364 | 0.220 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2023 | 4 | 0.220 |
Why?
|
| Leukopenia | 1 | 2023 | 4 | 0.220 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 48 | 0.220 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2023 | 9 | 0.210 |
Why?
|
| Terminal Care | 2 | 2020 | 34 | 0.210 |
Why?
|
| Noncommunicable Diseases | 1 | 2023 | 75 | 0.200 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 29 | 0.200 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 14 | 0.200 |
Why?
|
| Receptors, Progesterone | 2 | 2021 | 14 | 0.200 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 17 | 0.200 |
Why?
|
| Inosine Monophosphate | 1 | 2021 | 3 | 0.190 |
Why?
|
| Breast | 2 | 2021 | 10 | 0.190 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 53 | 0.190 |
Why?
|
| Odds Ratio | 1 | 2021 | 132 | 0.190 |
Why?
|
| Nasopharynx | 1 | 2021 | 148 | 0.180 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 243 | 0.180 |
Why?
|
| Aged | 3 | 2019 | 1650 | 0.170 |
Why?
|
| HIV | 1 | 2023 | 380 | 0.170 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 18 | 0.170 |
Why?
|
| Africa South of the Sahara | 1 | 2020 | 328 | 0.170 |
Why?
|
| Adult | 5 | 2023 | 5664 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 61 | 0.170 |
Why?
|
| Urban Population | 1 | 2021 | 246 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2019 | 58 | 0.160 |
Why?
|
| Self Report | 1 | 2019 | 111 | 0.160 |
Why?
|
| Death | 1 | 2019 | 14 | 0.160 |
Why?
|
| Terminally Ill | 1 | 2019 | 21 | 0.160 |
Why?
|
| Comorbidity | 1 | 2019 | 184 | 0.160 |
Why?
|
| Streptococcus pneumoniae | 1 | 2021 | 320 | 0.160 |
Why?
|
| Risk Assessment | 1 | 2019 | 217 | 0.160 |
Why?
|
| Hospitalization | 1 | 2021 | 392 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 3 | 2023 | 14 | 0.150 |
Why?
|
| Male | 4 | 2022 | 6489 | 0.150 |
Why?
|
| Age of Onset | 1 | 2018 | 32 | 0.150 |
Why?
|
| Viral Load | 1 | 2022 | 808 | 0.150 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 405 | 0.150 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 3 | 0.150 |
Why?
|
| Mastectomy | 1 | 2017 | 10 | 0.140 |
Why?
|
| Rural Population | 1 | 2021 | 624 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 1 | 2021 | 542 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2021 | 1675 | 0.140 |
Why?
|
| Infant | 1 | 2021 | 2145 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 32 | 0.100 |
Why?
|
| Genotype | 2 | 2023 | 430 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2023 | 464 | 0.100 |
Why?
|
| Palliative Care | 2 | 2020 | 50 | 0.080 |
Why?
|
| Medical Assistance | 1 | 2023 | 8 | 0.060 |
Why?
|
| Filgrastim | 1 | 2023 | 4 | 0.060 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 9 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 10 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 45 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2023 | 96 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 168 | 0.050 |
Why?
|
| Cholesterol | 1 | 2022 | 38 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 190 | 0.050 |
Why?
|
| ROC Curve | 1 | 2021 | 47 | 0.050 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2021 | 8 | 0.050 |
Why?
|
| United States | 1 | 2021 | 129 | 0.050 |
Why?
|
| Research Report | 1 | 2021 | 11 | 0.050 |
Why?
|
| Developing Countries | 1 | 2023 | 385 | 0.050 |
Why?
|
| Spirituality | 1 | 2020 | 11 | 0.040 |
Why?
|
| Pain | 1 | 2020 | 40 | 0.040 |
Why?
|
| Attitude to Death | 1 | 2019 | 6 | 0.040 |
Why?
|
| Quality of Life | 1 | 2020 | 170 | 0.040 |
Why?
|
| Caregivers | 1 | 2019 | 66 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 367 | 0.040 |
Why?
|
| Survival Rate | 1 | 2018 | 96 | 0.040 |
Why?
|
| Prognosis | 1 | 2018 | 197 | 0.040 |
Why?
|
| Risk Factors | 1 | 2021 | 1431 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 449 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1377 | 0.030 |
Why?
|